Quantoom and eTheRNA will work together to create an advanced, low-footprint technology platform for the production of affordable RNA-based therapies, which can be used either in existing facilities or rapidly deployed to areas of urgent need. Unlike existing large and expensive RNA production plants, the RPS will manufacture small, modular RNA units, which can be easily shipped to multiple geographic regions. The RPS is intended to be seamlessly scaled from small scale preclinical batches to mass production of GMP grade RNA. The only requirement will be that the RPS be located inside a suitable clean room with an uninterrupted power supply.
Under the terms of the agreement, eTheRNA will transfer the manufacturing technology to Quantoom with all the materials and data necessary for the development of the new RPS. After the completion of the RPS, Quantoom will be responsible for marketing the system globally, with royalties from sales payable to eTheRNA. International sales and distribution are expected to start in 2023 after the production of RPS in Belgium.
Bernard Sagaert, Senior Vice President ETheRNA Manufacturing and COO, commented, “This cooperation aligns with our goals for RNA production; namely cost reduction, process scalability from small to large scale, portability and process automation. Currently, the global supply of RNA is hampered by the lack of dedicated production facilities and the cost of building new factories. RPS will revolutionize the way RNA is produced and distributed globally and we are excited to be able to work with a leading developer and manufacturer like Quantoom to bring this vision to market.
José Castillo, CEO of Quantoom Biosciences, added: “We are delighted to enter into this collaborative agreement with eTheRNA, which has extensive experience in the field of RNA and, like Quantoom, has a mission to change the world of RNA. ‘RNA. With our combined know-how, I am confident that Quantoom will be able to develop an open and integrated RNA platform that will enable the manufacture of large-scale RNA vaccines and therapies, resulting in development and affordable production of RNA drugs. ”